Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray's 26th Annual Healthcare Conference

LOS ANGELES, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that CEO and President Linda Marbán will deliver an overview of Capricor Therapeutics, Inc., to Piper Jaffray's clients during a fireside chat session in the Rutherford Room of the New York Palace Hotel, December 2, 2014, at 9:00 a.m. EST.

Later that day at 2:00 p.m. EST, Dr. Marbán will also serve as an expert panelist during a special session on Heart Failure along with four other industry leaders at Piper Jaffray's 26th Annual Healthcare Conference, which will be co-moderated by Joshua Schimmer, M.D., senior biotechnology analyst and Ted Tenthoff, senior drug discovery analyst at Piper Jaffray.

"I am very pleased to present an overview of Capricor Therapeutics to Piper Jaffray's clients and join this panel of esteemed colleagues to discuss the latest scientific advances in heart failure," said Capricor CEO, Linda Marbán, Ph.D. "With Capricor's lead product candidates, CDCs (CAP-1002) and Cenderitide aiming to treat heart failure and its complications, I hope to be able to provide a forum for the investment community to better understand the importance of Capricor Therapeutics' platform technology and the necessity of working with leaders in the capital markets to move science and healthcare forward. I look forward to a dynamic and informative discussion."

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, in our Amendment No. 1 to Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on May 23, 2014, and in our Form 10-Q for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission on November 14, 2014. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

CONTACT: Capricor Therapeutics, Inc.
         AJ Bergmann, Vice President of Finance

         ProActive Capital Group
         Kirin Smith, COO

Capricor Therapeutics logo

Source: Capricor Therapeutics